A new Northwestern Medicine study has shed light on how a class of diabetes drugs may protect the kidneys—not just by lowering blood sugar, but by triggering a molecular shift that dampens inflammation, according to a study published in The Journal of Clinical Investigation.
This article was originally published on MedicalXpress.com